Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All drugs

Semaglutide

Wegovy

Stage ApprovedStale

Sponsor Novo Nordisk Inc.

Route injection and tablet

Class GLP-1 RA

Mechanism glucagon-like peptide-1 (GLP-1) receptor agonist

Target GLP-1 receptor

Sources

fda, as of 2026-05-05Stale

https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/215256Orig1s031.pdf

Sponsor: Novo Nordisk Inc. Trade Name: WEGOVY. Generic or Proper Name: semaglutide. WEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY injection is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity. WEGOVY tablets are indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity.

Approval package 215256Orig1s031, highlights and Table 8 Study 2 and Table 12 Study 8

registry, as of 2021-11-19Stale

https://clinicaltrials.gov/study/NCT03548935

Protocol section, NCT03548935, last update posted 2021-11-19

registry, as of 2026-04-23Stale

https://clinicaltrials.gov/study/NCT05646706

Protocol section, NCT05646706 STEP UP, last update posted 2026-04-23

registry, as of 2024-08-30Stale

https://clinicaltrials.gov/study/NCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 17604. Conditions Overweight; Obesity. The researchers are doing the study to see if semaglutide may reduce the risk of having cardiovascular events in patients with overweight or obesity and with prior cardiovascular disease. The participant will either get semaglutide (active medicine) or placebo ("dummy" medicine). Change in Body Weight Semaglutide -9.39 percentage change in body weight Week 0, week 104 Change in Body Weight Placebo -0.87 percentage change in body weight Week 0, week 104 Change in HbA1c - Percentage Semaglutide -0.31 Percentage of HbA1c Change in HbA1c - Percentage Placebo 0.01 Percentage of HbA1c Change in HbA1c - mmol/Mol Semaglutide -3.38 mmol/mol Change in HbA1c - mmol/Mol Placebo 0.1 mmol/mol de

ClinicalTrials.gov NCT03574597 protocol and results modules

registry, as of 2026-11-05

https://clinicaltrials.gov/study/NCT07866066

Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes. Overall status RECRUITING. Phases PHASE3. Lead sponsor Amgen. Enrollment 1300. Conditions Diabetes Mellitus, Type 2. The main objective of this trial is to evaluate whether maridebart cafraglutide is non-inferior to semaglutide in improving glycemic control in participants with type 2 diabetes (T2D) who are receiving metformin treatment, with or without a sodium-glucose cotransporter-2 (SGLT-2)

ClinicalTrials.gov NCT07866066 protocol and results modules

registry, as of 2026-10-06Stale

https://clinicaltrials.gov/study/NCT07284979

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Kailera. Enrollment 1270. Conditions Obesity. The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

ClinicalTrials.gov NCT07284979 protocol and results modules

registry, as of 2021-11-09Stale

https://clinicaltrials.gov/study/NCT03552757

Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 1210. Conditions Obesity; Overweight. This study will look at the change in the participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the study medicine, the Change in Body Weight (%) - Semaglutide 2.4 mg Versus Semaglutide 1.0 mg Semaglutide 2.4 mg -9.9 Percentage point of body weight Baseline (week 0) to week 68 Change in Body Weight (%) - Semaglutide 2.4 mg Versus Semaglutide 1.0 mg Semaglutide 1.0 mg -7.2 Percentage point of body weight Baseline (week 0) to week 68 Change in HbA1c (%) Semaglutide 1.0 mg -1.5 Percentage po

ClinicalTrials.gov NCT03552757 protocol and results modules

registry, as of 2026-03-12Stale

https://clinicaltrials.gov/study/NCT07400107

AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 1000. Conditions Obesity; Overweight; Diabetes Mellitus, Type 2. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. Participant will receive 2 injections every week: an active medicine and a placebo, both taken as injections under the skin

ClinicalTrials.gov NCT07400107 protocol and results modules

registry, as of 2022-01-19Stale

https://clinicaltrials.gov/study/NCT03548987

Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 902. Conditions Metabolism and Nutrition Disorder; Obesity. This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, the participa Change From Randomisation to Week 68 in Body Weight (%) In-trial Semaglutide 2.4 mg -8.3 Percentage point Randomisation (week 20) to week 68 Change From Randomisation to Week 68 in Body Weight (%) In-trial Placebo 6.5 Percentage point Randomisation (week 20) to week 68 Change From Randomisation to Week 68 in Body Weight (%) On-treatment Semaglutide 2.4 mg -8.8 Percentag

ClinicalTrials.gov NCT03548987 protocol and results modules

registry, as of 2025-11-26Stale

https://clinicaltrials.gov/study/NCT05822830

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities. Overall status COMPLETED. Phases PHASE3. Lead sponsor Eli Lilly and Company. Enrollment 751. Conditions Obesity; Overweight. The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks. Percentage of Participants Who Achieve ≥10% Body Weight Reduction 15 mg or MTD - Tirzepatide 87.7 Percentage of Participants Who Achieve ≥10% Body Weight Reduction 2.4 mg or MTD - Semaglutide 66.7 Percentage of Participants Who Achieve ≥15% Body Weight Reduction 15 mg or MTD - Tirzepatide 71.7 Percentage of Participants Who Achieve ≥15% Body Weight Reduction 2.4 mg or MTD - Semaglutide 45.0

ClinicalTrials.gov NCT05822830 protocol and results modules

registry, as of 2026-09-28Stale

https://clinicaltrials.gov/study/NCT07668414

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide. Overall status RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 650. Conditions Overweight; Obesity. The purpose of this study is to find out if zenagamtide is safe and effective for treating participants who have excess body weight compared to treatment with semaglutide.

ClinicalTrials.gov NCT07668414 protocol and results modules

registry, as of 2026-11-02

https://clinicaltrials.gov/study/NCT04916470

Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 617. Conditions Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2. This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight. This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart Percentage Change in Body Weight Semaglutide 2.4 mg -10.2 Percentage change in body weight Baseline (week 0), end of treatment (week 52) Percentage Change in Body Weight Placebo -3.2 Percentage change in body weight Baseline (week 0), end of treatment (week 52) Change in Glycated Haemoglobin (HbA1c) Semaglutide 2.4

ClinicalTrials.gov NCT04916470 protocol and results modules

registry, as of 2021-11-11Stale

https://clinicaltrials.gov/study/NCT03611582

Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 611. Conditions Overweight; Obesity. This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. Together with the medicine, the participant will Change in Body Weight (%) In-trial observation period Semaglutide 2.4 mg -16.5 Percentage Baseline (week 0) to week 68 Change in Body Weight (%) In-trial observation period Placebo -5.8 Percentage Baseline (week 0) to week 68 Change in Body Weight (%) On-treatment observation period Semaglutide 2.4 mg -17.6 Percentage Baseline (week 0) to week 68 Change in Body Weight (%)

ClinicalTrials.gov NCT03611582 protocol and results modules

registry, as of 2026-05-11Stale

https://clinicaltrials.gov/study/NCT05514535

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE). Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 573. Conditions Diabetes Mellitus, Type 2; Obesity. This study compares semaglutide, together with a lower dose of insulin glargine, to a higher dose of insulin glargine in participants with type 2 diabetes. The study looks at how well the study medicines control blood glucose levels. Participants will either get semaglutide toget Change in Glycated Haemoglobin (HbA1c) [Noninferiority] Insuline Glargine U100 (Reduced) + Semaglutide -1.37 Percentage point of HbA1c Change in Glycated Haemoglobin (HbA1c) [Noninferiority] Insuline Glargine U100 (Titrated) -0.65 Percentage point of HbA1c Change in Glycated Haemoglobi

ClinicalTrials.gov NCT05514535 protocol and results modules

registry, as of 2026-02-27Stale

https://clinicaltrials.gov/study/NCT07285902

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Fujian Shengdi Pharmaceutical Co., Ltd.. Enrollment 572. Conditions Obesity. This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity

ClinicalTrials.gov NCT07285902 protocol and results modules

registry, as of 2025-12-05Stale

https://clinicaltrials.gov/study/NCT04788511

Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 529. Conditions Obesity. This study will look at how the participants daily life is affected by their heart failure. The study will also look at the change in participants body weight from the start to the end of the study. This is to compare the effect on heart failure symptoms and on body weight in peo Change in Body Weight Semaglutide 2.4 mg -13.9 Percentage of body weight From baseline (week 0) to end of treatment (week 52) Change in Body Weight Placebo -2.5 Percentage of body weight From baseline (week 0) to end of treatment (week 52) Percentage of Participants Achieving 10 Percent (%) Weight Loss (Yes/No) Semaglutide 2.4 mg 34.1 Percentage of Participants Achieving 10 Percent (%) Weight Loss (Yes

ClinicalTrials.gov NCT04788511 protocol and results modules

registry, as of 2026-04-27Stale

https://clinicaltrials.gov/study/NCT05649137

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 512. Conditions Obesity; Diabetes Mellitus, Type 2. This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people t Relative Change in Body Weight Semaglutide 7.2 mg -13.5 Percentage (%) change in body weight Baseline (week 0), End of treatment (week 72) Relative Change in Body Weight Semaglutide 2.4 mg -10.7 Percentage (%) change in body weight Baseline (week 0), End of treatment (week 72) Relative Change in Body Weight Placebo -4.0 Percentage (%) change in body weight Baseline (week 0), E

ClinicalTrials.gov NCT05649137 protocol and results modules

registry, as of 2024-09-27Stale

https://clinicaltrials.gov/study/NCT06616961

Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Popular Medical College Hospital. Enrollment 480. Conditions Obesity; Type 2 Diabetes Mellitus (T2DM). The goal of this clinical trial is to learn if semaglutide can help with weight loss in overweight or obese adults in Bangladesh. The study will also look at how safe semaglutide is for these participants. The main questions to answers are given below: Does semaglutide help part

ClinicalTrials.gov NCT06616961 protocol and results modules

registry, as of 2026-04-06Stale

https://clinicaltrials.gov/study/NCT06604624

Semaglutide in Treatment of Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Enrollment 462. Conditions Weight Management. This is a multicenter, randomized, open, positive parallel controlled phase III clinical trial to compare the efficacy and safety of once-weekly HD1916 and semaglutide injection and to evaluate immunogenicity in obese non-diabetic adults.

ClinicalTrials.gov NCT06604624 protocol and results modules

registry, as of 2026-09-25Stale

https://clinicaltrials.gov/study/NCT06738979

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects. Overall status COMPLETED. Phases PHASE3. Lead sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Enrollment 408. Conditions Obesity. This is a multicenter, randomized, open, parallel, positive-controlled clinical study to evaluate the efficacy and safety of Semaglutide injection (TQF3510) developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. in obese subjects (BMI≥28 kg/m2). Equivalence tests were per

ClinicalTrials.gov NCT06738979 protocol and results modules

registry, as of 2025-11-17Stale

https://clinicaltrials.gov/study/NCT05064735

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 407. Conditions Obesity. This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on Percentage Change in Body Weight Semaglutide 2.4 mg -14.2 Percentage change in body weight Baseline (week 0), end of treatment (week 68) Percentage Change in Body Weight Placebo -2.5 Percentage change in body weight Baseline (week 0), end of treatment (week 68) Percentage of Participants Achieving Body Weight Reduction Greater Than or Equal to (≥) 5 Percent (%) (Yes/No) Semaglutide 2.4 mg 87.0 Per

ClinicalTrials.gov NCT05064735 protocol and results modules

registry, as of 2022-03-22Stale

https://clinicaltrials.gov/study/NCT03811574

STEP 6: Research Study Investigating How Well Semaglutide Works in People Living With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 401. Conditions Overweight; Obesity. This study will look at the change in participants' body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine, participants Change in Body Weight (%) Semaglutide 1.7 mg -9.9 Percentage change Baseline (week 0), week 68 Change in Body Weight (%) Semaglutide 2.4 mg -13.4 Percentage change Baseline (week 0), week 68 Change in Body Weight (%) Placebo -1.9 Percentage change Baseline (week 0), week 68 Change in HbA1c (%) Semaglutide 1.7 mg -0.9 Percentage of HbA1c Change in HbA1c (%) Semaglutide 2.4 mg -1.0 Percenta

ClinicalTrials.gov NCT03811574 protocol and results modules

registry, as of 2026-01-29Stale

https://clinicaltrials.gov/study/NCT04251156

Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 375. Conditions Overweight; Obesity; Diabetes Mellitus, Type 2. This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy" medicine. In addition to taking the medicine particip Change From Baseline in Body Weight (Percentage [%]) Semaglutide 2.4 mg -12.5 Percentage change Baseline (week 0), week 44 Change From Baseline in Body Weight (Percentage [%]) Placebo -3.6 Percentage change Baseline (week 0), week 44 Change From Baseline in Glycosylated Haemoglobin (HbA1c) (Percentage [%]) Semaglutide 2.4 mg -0.8 Percentage of HbA1c Change From Baseline in Glyco

ClinicalTrials.gov NCT04251156 protocol and results modules

registry, as of 2026-10-13Stale

https://clinicaltrials.gov/study/NCT07743983

A Study of BGM0504 in Early T2DM With Obesity. Overall status RECRUITING. Phases PHASE3. Lead sponsor BrightGene Bio-Medical Technology Co., Ltd.. Enrollment 372. Conditions Type 2 Diabetes (T2DM). This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise. Over 52 weeks of once weekly treatment, efficacy and safety are evaluated, including the

ClinicalTrials.gov NCT07743983 protocol and results modules

registry, as of 2024-10-09Stale

https://clinicaltrials.gov/study/NCT06633783

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®. Overall status UNKNOWN. Phases PHASE3. Lead sponsor Hangzhou Jiuyuan Gene Engineering Co. Ltd.,. Enrollment 370. Conditions Obesity. The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy®.

ClinicalTrials.gov NCT06633783 protocol and results modules

registry, as of 2026-06-03Stale

https://clinicaltrials.gov/study/NCT07622810

BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Carnot Laboratories. Enrollment 352. Conditions Obesity & Overweight. The goal of this clinical trial is to evaluate the efficacy and safety of Bofanglutide (GZR18) compared with Semaglutide in Latin American adults with overweight or obesity. It will also evaluate the effects of treatment on metabolic parameters, cardiovascular risk factors, and q

ClinicalTrials.gov NCT07622810 protocol and results modules

registry, as of 2023-07-06Stale

https://clinicaltrials.gov/study/NCT03693430

Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 304. Conditions Overweight; Obesity. This study will look at the change in body weight from the start to the end of the study. Researchers will compare the weight loss in people taking semaglutide (a new medicine) to people taking "dummy" medicine. In addition to taking the medicine, participants will also have talk Percentage Change From Baseline (Week 0) to Week 104 in Body Weight In-trial observation period Semaglutide 2.4 mg -15.9 percentage change From Baseline (Week 0) to Week 104 Percentage Change From Baseline (Week 0) to Week 104 in Body Weight In-trial observation period Placebo -1.9 percentage change From Baseline (Week 0) to Week 104 Percentage Change From Baseline (Week 0) to Week 1

ClinicalTrials.gov NCT03693430 protocol and results modules

registry, as of 2026-05-18Stale

https://clinicaltrials.gov/study/NCT06041217

A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 242. Conditions Overweight; Obesity. This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight. This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo). The study will last for about 1 y Change in Body Weight (%) Semaglutide 2.4 mg -12.2 Percentage change in body weight Baseline (week 0), end of treatment (week 44) Change in Body Weight (%) Placebo -2.2 Percentage change in body weight Baseline (week 0), end of treatment (week 44) Change in HbA1c (%) Semaglutide 2.4 mg -0.4 Percentage of HbA1c Change in HbA1c (%) Placebo 0.0 Percentage of HbA1c Change in HbA1c (mmol/

ClinicalTrials.gov NCT06041217 protocol and results modules

registry, as of 2026-10-07Stale

https://clinicaltrials.gov/study/NCT05726227

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight. Overall status ACTIVE_NOT_RECRUITING. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 212. Conditions Obesity. This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the c

ClinicalTrials.gov NCT05726227 protocol and results modules

registry, as of 2026-01-29Stale

https://clinicaltrials.gov/study/NCT05040971

Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 207. Conditions Obesity. This study looks at how well a new medicine, called semaglutide, works at helping people with obesity and prediabetes. This study will look at how much weight participants lose, and if participants can go from having blood sugar that is higher than normal (prediabetes) to having Change in Body Weight (Percentage [%]) Semaglutide 2.4 mg -14.4 Percentage (%) of body weight From randomisation (week 0) to end of treatment (week 52) Change in Body Weight (Percentage [%]) Placebo -2.7 Percentage (%) of body weight From randomisation (week 0) to end of treatment (week 52) Change in Glycosylated Haemoglobin (HbA1c) Semaglutide 2.4 mg -0.4 Percentage of HbA1c Change in Glycosylated Haemoglobi

ClinicalTrials.gov NCT05040971 protocol and results modules

registry, as of 2025-12-11Stale

https://clinicaltrials.gov/study/NCT04102189

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 201. Conditions Overweight; Obesity. This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents w Percentage of Participants Achieving Greater Than or Equal to (>=) 5% Reduction of Body Weight (Yes/no) Semaglutide 2.4 mg 72.5 Percentage of Participants Achieving Greater Than or Equal to (>=) 5% Reduction of Body Weight (Yes/no) Placebo 17.7 Percentage of Participants Achieving Greater Than or Equal to (>=) 5% Reduction of Body Weight (Yes/no) Semaglutide 2.4 mg 27.5 Percentage of Participants Achieving

ClinicalTrials.gov NCT04102189 protocol and results modules

registry, as of 2025-11-14Stale

https://clinicaltrials.gov/study/NCT06499857

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation. Overall status RECRUITING. Phases PHASE3. Lead sponsor University of Chicago. Enrollment 200. Conditions Overweight or Obesity; Atrial Fibrillation. The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard A

ClinicalTrials.gov NCT06499857 protocol and results modules

registry, as of 2026-09-02Stale

https://clinicaltrials.gov/study/NCT06934655

Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth. Overall status RECRUITING. Phases PHASE3. Lead sponsor Children's Hospital Los Angeles. Enrollment 150. Conditions Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide. This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who hav

ClinicalTrials.gov NCT06934655 protocol and results modules

registry, as of 2025-12-30Stale

https://clinicaltrials.gov/study/NCT04998136

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity. Overall status COMPLETED. Phases PHASE3. Lead sponsor Novo Nordisk A/S. Enrollment 150. Conditions Obesity. This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study. The study compares the weight loss in people who get semaglutide to the weight loss in people who get pla Change in Body Weight (%) : In-trial Observation Period Semaglutide -16.4 Percentage of body weight Baseline (week 0), end of treatment (week 44) Change in Body Weight (%) : In-trial Observation Period Placebo -2.6 Percentage of body weight Baseline (week 0), end of treatment (week 44) Change in Body Weight (%) : On-treatment Observation Period Semaglutide -16.4 Percentage of body weight Bas

ClinicalTrials.gov NCT04998136 protocol and results modules

registry, as of 2025-04-22Stale

https://clinicaltrials.gov/study/NCT04889183

SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes. Overall status COMPLETED. Phases PHASE3. Lead sponsor University Medical Center Groningen. Enrollment 125. Conditions Obesity; Albuminuria. Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression.

ClinicalTrials.gov NCT04889183 protocol and results modules

registry, as of 2025-08-08Stale

https://clinicaltrials.gov/study/NCT06909006

Semaglutide Treatment in Type 1 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor Nordsjaellands Hospital. Enrollment 122. Conditions Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diab. The goal of this clinical trial is to investigate the efficacy of semaglutide on body weight, insulin dose requirements and improvements in glucose control and safety aspects in regards to risk of hypoglycemia and diabetic ketoacidosis for patients with established Type 1 Diabete

ClinicalTrials.gov NCT06909006 protocol and results modules

registry, as of 2026-07-02Stale

https://clinicaltrials.gov/study/NCT07021937

Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity. Overall status NOT_YET_RECRUITING. Phases PHASE3. Lead sponsor University of Colorado, Denver. Enrollment 120. Conditions Obesity/Therapy. Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain ci

ClinicalTrials.gov NCT07021937 protocol and results modules

registry, as of 2024-10-15Stale

https://clinicaltrials.gov/study/NCT05087342

Latino Semaglutide Study. Overall status COMPLETED. Phases PHASE3. Lead sponsor Loma Linda University. Enrollment 119. Conditions Obesity; Obesity; Drug; Overweight or Obesity; Weight Loss; Weight Loss Trajectory; Weight, Body. The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.

ClinicalTrials.gov NCT05087342 protocol and results modules

Studies

STEP 1

Registry NCT03548935

Phase Phase 3

Status Completed

Enrollment 1961

Start 2018-06-04

Primary completion 2020-03-30

Study completion 2021-03-05

Semaglutide s.c. 2.4 mg once weekly

Dose 2.4 mg

Regimen once weekly

Weeks 68

Comparator placebo

Population obesity or overweight with comorbidity

Estimand ITT

percent change from baseline in body weight, -14.9 %, week 68Stale

percent difference from placebo in body weight, -12.4 %, week 68, vs placeboStale

patients losing greater than or equal to 5% body weight, 83.5 %, week 68Stale

Semaglutide placebo

Regimen once weekly

Weeks 68

Population obesity or overweight with comorbidity

Estimand ITT

percent change from baseline in body weight, -2.4 %, week 68Stale

patients losing greater than or equal to 5% body weight, 31.1 %, week 68Stale

STEP UP

Registry NCT05646706

Phase Phase 3

Status Completed

Enrollment 1407

Start 2023-01-04

Primary completion 2024-10-30

Study completion 2024-11-26

Semaglutide 7.2 mg

Dose 7.2 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population patients with obesity

Estimand ITT

percent change from baseline in body weight, -18.8 %, week 72Stale

percent difference from placebo in body weight, -14.9 %, week 72, vs placeboStale

patients losing greater than or equal to 5% body weight, 88.7 %, week 72Stale

permanent discontinuation as a result of adverse reactions, week 72, discontinuation 5.4%Stale

Semaglutide 2.4 mg

Dose 2.4 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population patients with obesity

Estimand ITT

percent change from baseline in body weight, -15.5 %, week 72Stale

Placebo

Regimen once weekly

Weeks 72

Population patients with obesity

Estimand ITT

percent change from baseline in body weight, -3.9 %, week 72Stale

patients losing greater than or equal to 5% body weight, 38.3 %, week 72Stale

permanent discontinuation as a result of adverse reactions, week 72, discontinuation 1%Stale

SELECT

Registry NCT03574597

EudraCT 2017-003380-35

Phase Phase 3

Status Completed

Enrollment 17604

Start 2018-10-24

Primary completion 2023-06-21

Study completion 2023-06-29

Semaglutide

Regimen once weekly

Weeks 4

Comparator placebo

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -9.39 %Stale

change in HbA1c, -0.31 Percentage of HbA1cStale

Placebo (semaglutide)

Regimen once weekly

Weeks 4

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -0.87 %Stale

change in HbA1c, 0.01 Percentage of HbA1cStale

deaths

participants with diarrhoea, 353 participantsStale

participants with nausea, 337 participantsStale

participants with vomiting, 87 participantsStale

MARITIME-T2D-3

Registry NCT07866066

Phase Phase 3

Status Recruiting

Enrollment 1300

Start 2026-10-16

Primary completion 2028-09-06

Study completion 2028-12-05

Catalyst Primary completion. 2028-09-06. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

Maridebart cafraglutide

Regimen every 4 weeks

Weeks 4

Population Diabetes Mellitus, Type 2

Semaglutide

Regimen once weekly

Weeks 4

Population Diabetes Mellitus, Type 2

KaiNETIC-3

Registry NCT07284979

Phase Phase 3

Status Active, not recruiting

Enrollment 1270

Start 2025-12-30

Ribupatide: Dose 1

Regimen once weekly

Comparator placebo

Population Obesity

Ribupatide: Dose 2

Regimen once weekly

Comparator placebo

Population Obesity

Semaglutide

Regimen once weekly

Comparator placebo

Population Obesity

Placebo

Regimen once weekly

Population Obesity

STEP 2

Registry NCT03552757

EudraCT 2017-003414-10

Phase Phase 3

Status Completed

Enrollment 1210

Start 2018-06-04

Primary completion 2020-03-24

Study completion 2020-05-01

Semaglutide 1.0 mg

Dose 1.0 mg

Regimen once weekly

Weeks 4

Comparator placebo

Population Obesity; Overweight

Estimand ITT

percent change in body weight, -7.2 %Stale

change in HbA1c, -1.5 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 88 participantsStale

participants with nausea, 128 participantsStale

participants with vomiting, 54 participantsStale

Semaglutide 2.4 mg

Dose 2.4 mg

Regimen once weekly

Weeks 4

Comparator placebo

Population Obesity; Overweight

Estimand ITT

percent change in body weight, -9.9 %Stale

change in HbA1c, -1.7 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 86 participantsStale

participants with nausea, 135 participantsStale

participants with vomiting, 86 participantsStale

Semaglutide placebo I/II

Regimen once weekly

Weeks 4

Population Obesity; Overweight

Estimand ITT

change in HbA1c, -0.3 Percentage point of HbA1cStale

deaths

participants with diarrhoea, 48 participantsStale

participants with nausea, 37 participantsStale

participants with vomiting, 11 participantsStale

AMAZE 8

Registry NCT07400107

Phase Phase 3

Status Not yet recruiting

Enrollment 1000

Start 2026-05-20

Primary completion 2028-12-12

Study completion 2029-01-26

Catalyst Primary completion. 2028-12-12. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

NNC0487-0111

Regimen once weekly

Population Obesity; Overweight; Diabetes Mellitus, Type 2

Semaglutide

Regimen once weekly

Population Obesity; Overweight; Diabetes Mellitus, Type 2

STEP 4

Registry NCT03548987

EudraCT 2017-003473-34

Phase Phase 3

Status Completed

Enrollment 902

Start 2018-06-04

Primary completion 2020-02-22

Study completion 2020-03-20

Semaglutide

Regimen every 4 weeks

Weeks 20

Comparator placebo

Population Metabolism and Nutrition Disorder; Obesity

Estimand Efficacy

percent change in body weight, -8.3 %, week 20Stale

Placebo

Regimen every 4 weeks

Weeks 20

Population Metabolism and Nutrition Disorder; Obesity

Estimand Efficacy

percent change in body weight, 6.5 %, week 20Stale

Semaglutide 2.4 mg, in trial

Dose 2.4 mg

Regimen once weekly

Weeks 20

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

change in HbA1c, -0.2 Percentage point of HbA1c, week 20Stale

percent change in body weight, -17.7 %Stale

Placebo, in trial

Regimen once weekly

Weeks 20

Population Metabolism and Nutrition Disorder; Obesity

Estimand ITT

change in HbA1c, 0.1 Percentage point of HbA1c, week 20Stale

percent change in body weight, -5.4 %Stale

deaths

participants with diarrhoea, 19 participantsStale

participants with nausea, 13 participantsStale

participants with vomiting, 8 participantsStale

SURMOUNT-5

Registry NCT05822830

Phase Phase 3

Status Completed

Enrollment 751

Start 2023-04-21

Primary completion 2024-11-13

Study completion 2024-11-13

15 mg or MTD - Tirzepatide

Dose 15 mg

Regimen once weekly

Weeks 72

Population Obesity; Overweight

participants with at least 10 percent body weight loss, 87.7 %, week 72Stale

participants with at least 15 percent body weight loss, 71.7 %, week 72Stale

participants with at least 20 percent body weight loss, 55 %, week 72Stale

deaths

participants with diarrhoea, 88 participantsStale

participants with nausea, 163 participantsStale

participants with vomiting, 56 participantsStale

2.4 mg or MTD - Semaglutide

Dose 2.4 mg

Regimen every 4 weeks

Weeks 72

Population Obesity; Overweight

participants with at least 10 percent body weight loss, 66.7 %, week 72Stale

participants with at least 15 percent body weight loss, 45 %, week 72Stale

participants with at least 20 percent body weight loss, 31.1 %, week 72Stale

deaths

participants with diarrhoea, 88 participantsStale

participants with nausea, 167 participantsStale

participants with vomiting, 80 participantsStale

AMAZE 7

Registry NCT07668414

Phase Phase 3

Status Recruiting

Enrollment 650

Start 2026-09-22

Primary completion 2028-10-10

Study completion 2028-10-10

Catalyst Primary completion. 2028-10-10. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Zenagamtide

Regimen once weekly

Population Overweight; Obesity

Semaglutide dose 1

Regimen once weekly

Population Overweight; Obesity

Semaglutide dose 2

Regimen once weekly

Population Overweight; Obesity

STEP HFpEF DM

Registry NCT04916470

EudraCT 2020-004170-22

Phase Phase 3

Status Completed

Enrollment 617

Start 2021-06-15

Primary completion 2023-10-11

Study completion 2023-10-11

Semaglutide 2.4 mg once weekly (OW)

Dose 2.4 mg

Regimen once weekly

Weeks 1

Comparator placebo

Population Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

Estimand ITT

percent change in body weight, -10.2 %

change in HbA1c, -0.8 Percentage of HbA1c

deaths

participants with diarrhoea, 42 participants

participants with nausea, 55 participants

participants with vomiting, 26 participants

Semaglutide placebo OW

Regimen once weekly

Weeks 1

Population Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

Estimand ITT

percent change in body weight, -3.2 %

change in HbA1c, 0.1 Percentage of HbA1c

deaths

participants with diarrhoea, 20 participants

participants with nausea, 18 participants

participants with vomiting, 7 participants

STEP 3

Registry NCT03611582

Phase Phase 3

Status Completed

Enrollment 611

Start 2018-08-01

Primary completion 2020-03-18

Study completion 2020-04-28

Semaglutide

Regimen once weekly

Weeks 4

Comparator placebo

Population Overweight; Obesity

Estimand Efficacy

percent change in body weight, -16.5 %Stale

Semaglutide placebo

Regimen once weekly

Weeks 4

Population Overweight; Obesity

Estimand Efficacy

percent change in body weight, -5.8 %Stale

Semaglutide 2.4 mg, in trial

Dose 2.4 mg

Regimen once weekly

Population Overweight; Obesity

Estimand ITT

change in HbA1c, -0.5 Percentage point of HbA1cStale

percent change in body weight, -7.8 %Stale

deaths

participants with diarrhoea, 147 participantsStale

participants with nausea, 237 participantsStale

participants with vomiting, 111 participantsStale

Placebo, in trial

Regimen once weekly

Population Overweight; Obesity

Estimand ITT

change in HbA1c, -0.3 Percentage point of HbA1cStale

percent change in body weight, -6 %Stale

deaths

participants with diarrhoea, 45 participantsStale

participants with nausea, 45 participantsStale

participants with vomiting, 22 participantsStale

A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (S

Registry NCT05514535

EudraCT 2021-004392-13

Phase Phase 3

Status Completed

Enrollment 573

Start 2022-08-29

Primary completion 2025-03-05

Study completion 2025-04-09

Catalyst Primary completion. 2025-03-05. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Insuline glargine U100 (reduced) + semaglutide

Regimen once weekly

Population Diabetes Mellitus, Type 2; Obesity

change in HbA1c, -1.37 Percentage point of HbA1cStale

Insuline glargine U100 (titrated)

Regimen once daily

Population Diabetes Mellitus, Type 2; Obesity

change in HbA1c, -0.65 Percentage point of HbA1cStale

A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

Registry NCT07285902

Phase Phase 3

Status Active, not recruiting

Enrollment 572

Start 2025-12-25

Treatment group A: HRS9531 injection

Regimen once weekly

Population Obesity

Treatment group B: Semaglutide Injection

Regimen once weekly

Population Obesity

STEP-HFpEF

Registry NCT04788511

EudraCT 2019-004452-11

Phase Phase 3

Status Completed

Enrollment 529

Start 2021-03-16

Primary completion 2023-04-18

Study completion 2023-04-18

Semaglutide

Regimen once weekly

Weeks 59

Comparator placebo

Population Obesity

Estimand ITT

percent change in body weight, -13.9 %Stale

participants with at least 10 percent body weight loss, 34.1 %Stale

participants with at least 15 percent body weight loss, 56.1 %Stale

participants with at least 20 percent body weight loss, 76.4 %Stale

Placebo (semaglutide)

Regimen once weekly

Weeks 59

Population Obesity

Estimand ITT

percent change in body weight, -2.5 %Stale

participants with at least 10 percent body weight loss, 90.5 %Stale

participants with at least 15 percent body weight loss, 97.9 %Stale

participants with at least 20 percent body weight loss, 99.6 %Stale

deaths

participants with diarrhoea, 10 participantsStale

participants with nausea, 7 participantsStale

participants with vomiting, 3 participantsStale

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Registry NCT05649137

EudraCT 2022-002235-60

Phase Phase 3

Status Completed

Enrollment 512

Start 2023-01-04

Primary completion 2024-10-28

Study completion 2024-12-13

Semaglutide 7.2 mg

Dose 7.2 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population Obesity; Diabetes Mellitus, Type 2

percent change in body weight, -13.5 %Stale

change in HbA1c, -1.8 Percentage of HbA1cStale

deaths

participants with diarrhoea, 56 participantsStale

participants with nausea, 89 participantsStale

participants with vomiting, 51 participantsStale

Semaglutide 2.4 mg

Dose 2.4 mg

Regimen once weekly

Weeks 72

Comparator placebo

Population Obesity; Diabetes Mellitus, Type 2

percent change in body weight, -10.7 %Stale

change in HbA1c, -1.7 Percentage of HbA1cStale

deaths

participants with diarrhoea, 21 participantsStale

participants with nausea, 29 participantsStale

participants with vomiting, 14 participantsStale

Placebo

Regimen once weekly

Weeks 72

Population Obesity; Diabetes Mellitus, Type 2

percent change in body weight, -4 %Stale

change in HbA1c, -0.3 Percentage of HbA1cStale

deaths

participants with diarrhoea, 9 participantsStale

participants with nausea, 12 participantsStale

participants with vomiting, 3 participantsStale

Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus

Registry NCT06616961

Phase Phase 3

Enrollment 480

Start 2024-11-01

Semaglutide

Regimen once weekly

Weeks 5

Population Obesity; Type 2 Diabetes Mellitus (T2DM)

Semaglutide in Treatment of Obesity

Registry NCT06604624

Phase Phase 3

Status Completed

Enrollment 462

Start 2024-09-20

Primary completion 2025-08-27

Study completion 2025-09-24

Catalyst Primary completion. 2025-08-27. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

HD1916

Regimen once weekly

Population Weight Management

semaglutide

Regimen once weekly

Population Weight Management

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Registry NCT06738979

Phase Phase 3

Status Completed

Enrollment 408

Start 2025-03-20

Primary completion 2026-03-07

Study completion 2026-05-26

Catalyst Primary completion. 2026-03-07. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

TQF3510

Population Obesity

Wegovy®

Population Obesity

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

Registry NCT05064735

EudraCT 2020-000204-11

Phase Phase 3

Status Completed

Enrollment 407

Start 2021-10-01

Primary completion 2023-07-24

Study completion 2023-09-08

semaglutide 2.4 mg

Dose 2.4 mg

Regimen once weekly

Comparator placebo

Population Obesity

Estimand ITT

percent change in body weight, -14.2 %Stale

participants with at least 5 percent body weight loss, 87 %Stale

participants with at least 10 percent body weight loss, 70.4 %Stale

participants with at least 15 percent body weight loss, 47.8 %Stale

participants with at least 20 percent body weight loss, 23.3 %Stale

semaglutide 2.4 mg (placebo)

Dose 2.4 mg

Regimen once weekly

Population Obesity

Estimand ITT

percent change in body weight, -2.5 %Stale

participants with at least 5 percent body weight loss, 29.2 %Stale

participants with at least 10 percent body weight loss, 9.2 %Stale

participants with at least 15 percent body weight loss, 2.5 %Stale

participants with at least 20 percent body weight loss, 0 %Stale

deaths

participants with diarrhoea, 21 participantsStale

participants with nausea, 59 participantsStale

participants with vomiting, 21 participantsStale

STEP 6

Registry NCT03811574

Phase Phase 3

Status Completed

Enrollment 401

Start 2019-01-21

Primary completion 2020-11-20

Study completion 2020-11-20

Semaglutide 2.4 mg

Dose 2.4 mg

Regimen once weekly

Weeks 68

Comparator placebo

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -13.4 %Stale

change in HbA1c, -1 Percentage of HbA1cStale

Placebo (semaglutide 2.4 mg)

Dose 2.4 mg

Regimen once weekly

Weeks 68

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -1.9 %Stale

change in HbA1c, 0 Percentage of HbA1cStale

deaths

participants with diarrhoea, 32 participantsStale

participants with nausea, 35 participantsStale

participants with vomiting, 17 participantsStale

Semaglutide 1.7 mg

Dose 1.7 mg

Regimen once weekly

Weeks 68

Comparator placebo

Population Overweight; Obesity

Estimand ITT

percent change in body weight, -9.9 %Stale

change in HbA1c, -0.9 Percentage of HbA1cStale

Placebo (semaglutide 1.7 mg)

Dose 1.7 mg

Regimen once weekly

Weeks 68

Population Overweight; Obesity

deaths

participants with diarrhoea, 22 participantsStale

participants with nausea, 18 participantsStale

participants with vomiting, 10 participantsStale

STEP7

Registry NCT04251156

Phase Phase 3

Status Completed

Enrollment 375

Start 2020-12-08

Primary completion 2022-08-23

Study completion 2022-08-23

Semaglutide

Regimen once weekly

Weeks 44

Comparator placebo

Population Overweight; Obesity; Diabetes Mellitus, Type 2

Estimand ITT

percent change in body weight, -12.5 %Stale

change in HbA1c, -0.8 Percentage of HbA1cStale

Placebo (semaglutide)

Regimen once weekly

Weeks 44

Population Overweight; Obesity; Diabetes Mellitus, Type 2

Estimand ITT

percent change in body weight, -3.6 %Stale

change in HbA1c, -0.1 Percentage of HbA1cStale

deaths

participants with diarrhoea, 13 participantsStale

participants with nausea, 9 participantsStale

participants with vomiting, 0 participantsStale

A Study of BGM0504 in Early T2DM With Obesity

Registry NCT07743983

Phase Phase 3

Status Recruiting

Enrollment 372

Start 2026-09-17

Primary completion 2028-09-30

Study completion 2028-11-30

Catalyst Primary completion. 2028-09-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

BGM0504 Injection 15 mg

Dose 15 mg

Regimen once weekly

Weeks 52

Population Type 2 Diabetes (T2DM)

Semaglutide Injection 1.0 mg

Dose 1.0 mg

Regimen once weekly

Weeks 52

Population Type 2 Diabetes (T2DM)

A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®

Registry NCT06633783

Phase Phase 3

Enrollment 370

Start 2024-10-30

Primary completion 2026-05-30

Study completion 2026-10-30

Catalyst Primary completion. 2026-05-30. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide injection

Regimen once weekly

Weeks 4

Population Obesity

Wegovy®

Regimen once weekly

Weeks 4

Population Obesity

BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

Registry NCT07622810

Phase Phase 3

Status Not yet recruiting

Enrollment 352

Group A: Bofanglutida (GZR18),

Regimen once weekly

Weeks 36

Population Obesity & Overweight

Group B: Semaglutide

Regimen once weekly

Weeks 36

Population Obesity & Overweight

STEP 5

Registry NCT03693430

EudraCT 2017-003726-32

Phase Phase 3

Status Completed

Enrollment 304

Start 2018-10-05

Primary completion 2021-01-29

Study completion 2021-03-23

Semaglutide

Regimen once weekly

Weeks 4

Comparator placebo

Population Overweight; Obesity

Estimand Efficacy

percent change in body weight, -15.9 %Stale

Placebo

Regimen once weekly

Weeks 4

Population Overweight; Obesity

Estimand Efficacy

percent change in body weight, -1.9 %Stale

Semaglutide 2.4 mg, in trial

Dose 2.4 mg

Regimen once weekly

Population Overweight; Obesity

Estimand ITT

change in HbA1c, -0.5 Percent of glycated haemoglobinStale

percent change in body weight, -15.8 %Stale

deaths

participants with diarrhoea, 53 participantsStale

participants with nausea, 81 participantsStale

participants with vomiting, 46 participantsStale

Placebo, in trial

Regimen once weekly

Population Overweight; Obesity

Estimand ITT

change in HbA1c, -0.1 Percent of glycated haemoglobinStale

percent change in body weight, -3.3 %Stale

deaths

participants with diarrhoea, 36 participantsStale

participants with nausea, 33 participantsStale

participants with vomiting, 7 participantsStale

STEP12

Registry NCT06041217

Phase Phase 3

Status Completed

Enrollment 242

Start 2023-09-15

Primary completion 2025-04-02

Study completion 2025-05-07

Catalyst Primary completion. 2025-04-02. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Semaglutide 2.4 milligram (mg)

Regimen once weekly

Weeks 44

Comparator placebo

Population Overweight; Obesity

Placebo

Regimen once weekly

Weeks 44

Population Overweight; Obesity

percent change in body weight, -2.2 %Stale

change in HbA1c, 0 Percentage of HbA1cStale

deaths

participants with diarrhoea, 6 participantsStale

participants with nausea, 2 participantsStale

participants with vomiting, 0 participantsStale

Semaglutide 2.4 mg

Dose 2.4 mg

Regimen once weekly

Population Overweight; Obesity

percent change in body weight, -12.2 %Stale

change in HbA1c, -0.4 Percentage of HbA1cStale

deaths

participants with diarrhoea, 30 participantsStale

participants with nausea, 29 participantsStale

participants with vomiting, 16 participantsStale

STEP Young

Registry NCT05726227

EudraCT 2022-502922-41

Phase Phase 3

Status Active, not recruiting

Enrollment 212

Start 2023-07-07

Primary completion 2025-10-15

Study completion 2026-12-07

Catalyst Primary completion. 2025-10-15. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Group Kids

Regimen once weekly

Population Obesity

Group Teens

Regimen once weekly

Population Obesity

STEP 10

Registry NCT05040971

EudraCT 2020-002939-29

Phase Phase 3

Status Completed

Enrollment 207

Start 2021-09-06

Primary completion 2023-01-06

Study completion 2023-07-14

Semaglutide

Regimen once weekly

Weeks 52

Comparator placebo

Population Obesity

Estimand ITT

percent change in body weight, -14.4 %Stale

change in HbA1c, -0.4 Percentage of HbA1cStale

Placebo (semaglutide)

Regimen once weekly

Weeks 52

Population Obesity

Estimand ITT

percent change in body weight, -2.7 %Stale

change in HbA1c, 0.1 Percentage of HbA1cStale

deaths

participants with diarrhoea, 7 participantsStale

participants with nausea, 3 participantsStale

participants with vomiting, 1 participantsStale

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

Registry NCT04102189

EudraCT 2018-002431-18

Phase Phase 3

Status Completed

Enrollment 201

Start 2019-10-07

Primary completion 2022-03-25

Study completion 2022-03-28

Semaglutide

Regimen once weekly

Weeks 16

Comparator placebo

Population Overweight; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 72.5 %, week 68Stale

percent change in body weight, -14.8 %Stale

participants with at least 10 percent body weight loss, 61.8 %, week 68Stale

participants with at least 15 percent body weight loss, 53.4 %, week 68Stale

participants with at least 20 percent body weight loss, 37.4 %, week 68Stale

change in HbA1c, -0.4 Percentage of HbA1cStale

Placebo

Regimen once weekly

Weeks 16

Population Overweight; Obesity

Estimand ITT

participants with at least 5 percent body weight loss, 17.7 %, week 68Stale

percent change in body weight, 2.3 %Stale

participants with at least 10 percent body weight loss, 8.1 %, week 68Stale

participants with at least 15 percent body weight loss, 4.8 %, week 68Stale

participants with at least 20 percent body weight loss, 3.2 %, week 68Stale

change in HbA1c, -0.1 Percentage of HbA1cStale

deaths

participants with diarrhoea, 13 participantsStale

participants with nausea, 12 participantsStale

participants with vomiting, 7 participantsStale

SEMINAL-AF

Registry NCT06499857

Phase Phase 3

Status Recruiting

Enrollment 200

Start 2025-04-14

Semaglutide

Comparator placebo

Population Overweight or Obesity; Atrial Fibrillation

Placebo

Population Overweight or Obesity; Atrial Fibrillation

Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth

Registry NCT06934655

Phase Phase 3

Status Recruiting

Enrollment 150

Start 2026-09-01

Primary completion 2030-11-01

Study completion 2033-11-01

Catalyst Primary completion. 2030-11-01. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale

Standard Care

Regimen weekly

Weeks 2

Population Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide

Early reinitiation

Regimen weekly

Weeks 2

Population Pediatric Obesity; Metabolic and Bariatric Surgery; Semaglutide

Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

Registry NCT04998136

Phase Phase 3

Status Completed

Enrollment 150

Start 2022-08-15

Primary completion 2023-10-16

Study completion 2023-11-20

Semaglutide 2.4 mg

Dose 2.4 mg

Regimen once weekly

Weeks 50

Comparator placebo

Population Obesity

Estimand ITT

percent change in body weight, -16.4 %Stale

participants with at least 5 percent body weight loss, 96 %, week 44Stale

change in HbA1c, -0.4 Percentage of HbA1cStale

Placebo

Regimen once weekly

Weeks 50

Population Obesity

Estimand ITT

percent change in body weight, -2.6 %Stale

participants with at least 5 percent body weight loss, 12 %, week 44Stale

change in HbA1c, 0 Percentage of HbA1cStale

Semaglutide, on treatment

Regimen once weekly

Weeks 44

Population Obesity

Estimand Efficacy

percent change in body weight, -16.4 %Stale

participants with at least 5 percent body weight loss, 92 %, week 44Stale

Placebo, on treatment

Regimen once weekly

Weeks 44

Population Obesity

Estimand Efficacy

percent change in body weight, -2.7 %Stale

participants with at least 5 percent body weight loss, 12 %, week 44Stale

deaths

participants with diarrhoea, 3 participantsStale

participants with nausea, 7 participantsStale

participants with vomiting, 2 participantsStale

SMART

Registry NCT04889183

EudraCT 2021-001247-27

Phase Phase 3

Status Completed

Enrollment 125

Start 2022-03-14

Primary completion 2024-05-28

Study completion 2024-05-28

Semaglutide

Regimen once weekly

Weeks 24

Comparator placebo

Population Obesity; Albuminuria

Placebo

Regimen once weekly

Weeks 24

Population Obesity; Albuminuria

OBES1TY

Registry NCT06909006

Phase Phase 3

Status Not yet recruiting

Enrollment 122

Semaglutide

Regimen once weekly

Comparator placebo

Population Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diab

Semaglutide placebo

Regimen once weekly

Population Obesity in Diabetes; Obesity/Therapy; Type 1 Diabetes Mellitus (T1DM); Insulin Sensitivity/Resistance; Semaglutide; Lipidomics; Metabolomics; Weight Loss; Glycemic Control for Diab

PLASTIC

Registry NCT07021937

Phase Phase 3

Status Not yet recruiting

Enrollment 120

Start 2026-06-15

Primary completion 2031-04-30

Study completion 2031-04-30

Pubertal Adolescent - Continuous Treatment

Population Obesity/Therapy

Pubertal Adolescent - Early Treatment Cessation

Population Obesity/Therapy

Post-Pubertal Adolescent - Continuous Treatment

Population Obesity/Therapy

Post-Pubertal Adolescent - Early Treatment Cessation

Population Obesity/Therapy

Adult - Continuous Treatment

Population Obesity/Therapy

Adult - Early Treatment Cessation

Population Obesity/Therapy

LSS

Registry NCT05087342

Phase Phase 3

Status Completed

Enrollment 119

Start 2022-12-13

Primary completion 2024-05-29

Study completion 2024-05-29

Intervention Group

Regimen once weekly

Weeks 4

Comparator placebo

Population Obesity; Obesity; Drug; Overweight or Obesity; Weight Loss; Weight Loss Trajectory; Weight, Body

Control Group

Regimen once weekly

Weeks 4

Population Obesity; Obesity; Drug; Overweight or Obesity; Weight Loss; Weight Loss Trajectory; Weight, Body